Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Hrkac FrederickOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:500,000Price:--
-
Dec 28, 2023 (filed on Jan 04, 2024)Insider Name:Hrkac FrederickOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:900,000Price:--
-
Dec 28, 2023 (filed on Jan 04, 2024)Insider Name:Hrkac FrederickOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:600,000Price:--
-
Nov 30, 2023 (filed on Dec 05, 2023)Insider Name:Sieckhaus JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:92,300Price:--
-
Nov 30, 2023 (filed on Dec 05, 2023)Insider Name:Fleming GrayOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:131,900Price:--
-
Nov 30, 2023 (filed on Dec 04, 2023)Insider Name:Sieckhaus JohnOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:92,300Price:--
-
Nov 30, 2023 (filed on Dec 04, 2023)Insider Name:Fleming GrayOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:131,900Price:--
-
Nov 30, 2023 (filed on Dec 04, 2023)Insider Name:Londoner Kenneth LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:219,700Price:--
-
Aug 15, 2023 (filed on Aug 18, 2023)Insider Name:Weild IV DavidOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:16,000Price:--
-
Aug 15, 2023 (filed on Aug 18, 2023)Insider Name:Klein James LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:16,000Price:--
Filings by filing date
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Hrkac FrederickOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:500,000Price:--
-
Dec 28, 2023 (filed on Jan 04, 2024)Insider Name:Hrkac FrederickOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:900,000Price:--
-
Dec 28, 2023 (filed on Jan 04, 2024)Insider Name:Hrkac FrederickOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:600,000Price:--
-
Nov 30, 2023 (filed on Dec 05, 2023)Insider Name:Sieckhaus JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:92,300Price:--
-
Nov 30, 2023 (filed on Dec 05, 2023)Insider Name:Fleming GrayOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:131,900Price:--
-
Nov 30, 2023 (filed on Dec 04, 2023)Insider Name:Sieckhaus JohnOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:92,300Price:--
-
Nov 30, 2023 (filed on Dec 04, 2023)Insider Name:Fleming GrayOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:131,900Price:--
-
Nov 30, 2023 (filed on Dec 04, 2023)Insider Name:Londoner Kenneth LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:219,700Price:--
-
Aug 15, 2023 (filed on Aug 18, 2023)Insider Name:Weild IV DavidOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:16,000Price:--
-
Aug 15, 2023 (filed on Aug 18, 2023)Insider Name:Klein James LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:16,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 55 Greens Farms Road WESTPORT CT 06880 |
Tel: | N/A |
Website: | https://www.biosig.com |
IR: | See website |
Key People | ||
Frederick D. Hrkac President, Principal Executive Officer, Director |
Business Overview |
BioSig Technologies, Inc. is a medical technology company focused on deciphering the body's electrical signals, starting with heart rhythms. The Company's product, the PURE EP Platform, a non-invasive class II device, provides real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures. Integrating with existing systems in the EP lab, PURE EP is designed to pinpoint even the complex signals to maximize procedural success and efficiency. The PURE EP System is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise from other equipment, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP is a signal processing platform that combines advanced hardware and software to address known challenges associated to signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time. |
Financial Overview |
For the fiscal year ended 31 December 2023, BioSig Technologies Inc revenues decreased 94% to $18K. Net loss applicable to common stockholders increased 7% to $29.1M. Revenues reflect Product decrease from $254K to $0K, Service decrease of 44% to $18K. Higher net loss reflects BioSig Technologies Inc segment loss increase of 10% to $29.3M, BioSig AI sciences Inc segment loss increase of 11% to $745K. |
Employees: | 4 as of Apr 15, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $15.15M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.02M as of Dec 31, 2023 |
EBITDA (TTM): | -$28.15M as of Dec 31, 2023 |
Net annual income (TTM): | -$29.05M as of Dec 31, 2023 |
Free cash flow (TTM): | -$17.50M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 11,198,174 as of Apr 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |